PRTA icon

Prothena Corp

8.38 USD
-0.39
4.45%
At close Aug 25, 4:00 PM EDT
After hours
8.33
-0.05
0.60%
1 day
-4.45%
5 days
-1.53%
1 month
25.45%
3 months
82.97%
6 months
-42.72%
Year to date
-38.70%
1 year
-61.87%
5 years
-35.39%
10 years
-84.07%
 

About: Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Employees: 163

0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

126% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 23

27% more call options, than puts

Call options by funds: $4.37M | Put options by funds: $3.43M

27% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 41

15% more funds holding

Funds holding: 159 [Q1] → 183 (+24) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

19.73% less ownership

Funds ownership: 97.07% [Q1] → 77.35% (-19.73%) [Q2]

61% less capital invested

Capital invested by funds: $647M [Q1] → $253M (-$394M) [Q2]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$4
52%
downside
Avg. target
$24
190%
upside
High target
$81
867%
upside

7 analyst ratings

positive
71%
neutral
14%
negative
14%
RBC Capital
Brian Abrahams
19%upside
$10
Sector Perform
Maintained
5 Aug 2025
HC Wainwright & Co.
Andrew S. Fein
67%upside
$14
Buy
Reiterated
5 Aug 2025
Chardan Capital
Rudy Li
115%upside
$18
Buy
Maintained
5 Aug 2025
B of A Securities
Tazeen Ahmad
52%downside
$4
Underperform
Downgraded
28 May 2025
Piper Sandler
Yasmeen Rahimi
867%upside
$81
Overweight
Maintained
27 May 2025

Financial journalist opinion

Based on 5 articles about PRTA published over the past 30 days

Neutral
Business Wire
2 weeks ago
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
Negative
The Motley Fool
2 weeks ago
Prothena Q2 Revenue Drops 97%
Prothena (PRTA 3.96%), a biotechnology company focused on developing therapies for neurodegenerative diseases, released its second quarter 2025 results on August 4, 2025. The period saw notably weaker-than-expected performance, with GAAP EPS of -2.34 missing the analysts' estimate of -1.25 and a much larger GAAP net loss than anticipated.
Prothena Q2 Revenue Drops 97%
Negative
Zacks Investment Research
3 weeks ago
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to earnings of $1.22 per share a year ago.
Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates
Neutral
Business Wire
3 weeks ago
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena today reported financial results for the second quarter and first six months of 2025 and provided business highlights.
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
Neutral
Business Wire
4 weeks ago
Prothena to Report Second Quarter 2025 Financial Results on August 4
DUBLIN--(BUSINESS WIRE)--Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.
Prothena to Report Second Quarter 2025 Financial Results on August 4
Negative
Zacks Investment Research
1 month ago
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
Neutral
Business Wire
2 months ago
Prothena Announces Corporate Restructuring
DUBLIN--(BUSINESS WIRE)--Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.
Prothena Announces Corporate Restructuring
Neutral
Business Wire
2 months ago
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson's disease.
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
Negative
Zacks Investment Research
2 months ago
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down
Neutral
Benzinga
2 months ago
Why Is Prothena Stock Trading Lower On Tuesday?
Prothena Corporation plc PRTA released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday.
Why Is Prothena Stock Trading Lower On Tuesday?
Charts implemented using Lightweight Charts™